tranexamic acid
Pre-clinical- Indications
- Traumatic bleeding, Hemorrhage
Company intelligence / Profile preview
MACH32 has developed IMSAFE, a novel high-volume intramuscular autoinjector for rapid delivery of tranexamic acid to treat life-threatening bleeding. Functional prototypes have been tested with military partners. The company has received BARDA funding to advance development and aims for regulatory submission with the FDA and Health Canada. No clinical trial results are yet available; preclinical testing and regulatory preparations are ongoing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MACH32.